APA (7th ed.) Citation

Park SH, Han X, Lobo F, Nanji S, & Patel D. (2020). A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity. Dove Medical Press.

Chicago Style (17th ed.) Citation

Park SH, Han X, Lobo F, Nanji S, and Patel D. A Cost Per Responder Model for Abatacept Versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity. Dove Medical Press, 2020.

MLA (9th ed.) Citation

Park SH, et al. A Cost Per Responder Model for Abatacept Versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity. Dove Medical Press, 2020.